The Cancer Genome Project intends to search every human gene for cancer-related mutations. Its first success is the discovery of such mutations in the BRAF gene.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review
Future Journal of Pharmaceutical Sciences Open Access 16 October 2023
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Davies, H. et al. Nature 417, 949–954 (2002); advance online publication, 9 June 2002 (doi:10.1038/nature00766).
Balmain, A. Nature Rev. Cancer 1, 77–82 (2001).
Lander, E. S. et al. Nature 409, 860–921 (2001).
Venter, J. C. et al. Science 291, 1304–1351 (2001).
Zhang, B. H. & Guan, K. L. EMBO J. 19, 5429–5439 (2000).
Pollock, P. M., Welch, J. & Hayward, N. K. Cancer Res. 61, 1154–1161 (2001).
Busca, R. et al. EMBO J. 19, 2900–2910 (2000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pollock, P., Meltzer, P. Lucky draw in the gene raffle. Nature 417, 906–907 (2002). https://doi.org/10.1038/417906a
Issue Date:
DOI: https://doi.org/10.1038/417906a
This article is cited by
-
Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review
Future Journal of Pharmaceutical Sciences (2023)
-
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Nature Reviews Cancer (2004)
-
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Oncogene (2003)
-
Issues and progress with protein kinase inhibitors for cancer treatment
Nature Reviews Drug Discovery (2003)